HOTHHoth Therapeutics, Inc.

Nasdaq hoththerapeutics.com


$ 1.17 $ 0.07 (6.25 %)    

Wednesday, 11-Sep-2024 15:55:51 EDT
QQQ $ 468.86 $ 0.00 (0 %)
DIA $ 409.73 $ 1.01 (0.25 %)
SPY $ 554.79 $ 5.63 (1.03 %)
TLT $ 100.61 $ -0.08 (-0.08 %)
GLD $ 232.25 $ -0.37 (-0.16 %)
$ 1.19
$ 1.17 x 100
-- x --
-- - --
$ 0.58 - $ 3.37
920,549
na
8.22M
$ 0.95
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-09-2024 06-30-2024 10-Q
2 05-14-2024 03-31-2024 10-Q
3 03-28-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-11-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-31-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-12-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-29-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-11-2021 06-30-2021 10-Q
14 05-13-2021 03-31-2021 10-Q
15 03-16-2021 12-31-2020 10-K
16 11-10-2020 09-30-2020 10-Q
17 08-13-2020 06-30-2020 10-Q
18 05-13-2020 03-31-2020 10-Q
19 03-02-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
21 08-14-2019 06-30-2019 10-Q
22 05-15-2019 03-31-2019 10-Q
23 04-01-2019 12-31-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ef-hutton-maintains-buy-on-hoth-therapeutics-maintains-5-price-target

EF Hutton analyst Jason Kolbert maintains Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $5 price target.

 hoth-therapeutics-received-institutional-review-board-approval-from-the-montefiore-medical-center-and-the-dana-farber-cancer-institute-to-proceed-with-its-first-in-human-phase-2a-clinical-trial-of-ht-001-for-the-treatment-of-skin-toxicities-associated-with-epidermal-growth-factor-receptor-inhibitors

Dana-Farber Cancer Institute in Boston, MA and Montefiore Medical Center in New York, NY Join Clinical TrialNEW YORK, Sept. 5, ...

 hc-wainwright--co-reiterates-buy-on-hoth-therapeutics-maintains-4-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $4 pr...

 hc-wainwright--co-reiterates-buy-on-hoth-therapeutics-maintains-4-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $4 pr...

Core News & Articles
Market-Moving News for July 24th
07/24/2024 12:34:15

TSLA: -8.8% | Tesla shares are trading lower following mixed Q2 earnings. The company also said it expects 2024 vehicle volume ...

 hc-wainwright--co-reiterates-buy-on-hoth-therapeutics-maintains-4-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $4 pr...

 hoth-therapeutics-approved-to-proceed-with-first-in-human-phase-2a-clinical-trial-of-ht-001-for-treatment-of-skin-toxicities-associated-with-epidermal-growth-factor-receptor-inhibitors

Three New Sites Join HT-001 Trial, GW University Hospital, UC Irvine and Northwell Health

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION